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ABSTRACT
Introduction Integration of smoking cessation (SC) into 
lung cancer screening is essential to optimise clinical and 
cost effectiveness. The most effective way to use this 
‘teachable moment’ is unclear. The Yorkshire Enhanced 
Stop Smoking study will measure the effectiveness of an 
SC service integrated within the Yorkshire Lung Screening 
Trial (YLST) and will test the efficacy of a personalised SC 
intervention, incorporating incidental findings detected on 
the low- dose CT scan performed as part of YLST.
Methods and analysis Unless explicitly declined, all 
smokers enrolled in YLST will see an SC practitioner 
at baseline and receive SC support over 4 weeks 
comprising behavioural support, pharmacotherapy and/or 
a commercially available e- cigarette. Eligible smokers will 
be randomised (1:1 in permuted blocks of random size up 
to size 6) to receive either an enhanced, personalised SC 
support package, including CT scan images, or continued 
standard best practice. Anticipated recruitment is 1040 
smokers (January 2019–December 2020). The primary 
objective is to measure 7- day point prevalent carbon 
monoxide (CO) validated SC after 3 months. Secondary 
outcomes include CO validated cessation at 4 weeks and 
12 months, self- reported continuous cessation at 4 weeks, 
3 months and 12 months, attempts to quit smoking and 
changes in psychological variables, including perceived 
risk of lung cancer, motivation to quit smoking tobacco, 
confidence and efficacy beliefs (self and response) at all 
follow- up points. A process evaluation will explore under 
which circumstances and on which groups the intervention 
works best, test intervention fidelity and theory test the 
mechanisms of intervention impact.
Ethics and dissemination This study has been 
approved by the East Midlands- Derby Research Ethics 
Committee (18/EM/0199) and the Health Research 
Authority/Health and Care Research Wales. Results will 
be disseminated through publication in peer- reviewed 
scientific journals, presentation at conferences and via 
the YLST website.
Trial registration numbers ISRCTN63825779, 
NCT03750110.
INTRODUCTION
Lung cancer is the third most common cancer 
and has the highest mortality of all cancers 
in the UK.1 It becomes more common as 
socioeconomic deprivation levels increase,2 
reflecting higher smoking rates.3 A reduction 
in both all- cause and lung cancer specific 
mortality was reported by the US National 
Lung Screening Trial in 20114; subsequently 
lung cancer screening (LCS) was adopted 
across North America having been recom-
mended by the US Preventive Services Task 
Strengths and limitations of this study
 ► This is the first study to investigate the use of inci-
dental findings as part of a smoking cessation (SC) 
intervention delivered alongside lung cancer screen-
ing, and to evaluate the uptake and effectiveness of 
a colocated stop smoking service.
 ► Recruitment is limited to the number of eligible 
smokers attending for a lung health check as part of 
the Yorkshire Lung Screening Trial.
 ► SC support will be consistently delivered in line with 
National Health Service best practice and National 
Institute for Health and Care Excellence guidance.
 ► The scripted approach to explaining lung scan re-
sults will support standardisation of intervention 
delivery.
 ► The inclusion of a process evaluation will enhance 
contextual understanding of study outcomes, includ-
ing why eligible individuals do not engage with the 
SC intervention.
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Force in 2013.5 Mortality benefits of low- dose CT (LDCT) 
screening for LCS have subsequently been demonstrated by 
the Multicentric Italian Lung Detection (MILD) trial6 and 
confirmed by preliminary results from the NELSON study.7
More than 85% of cases of lung cancer are caused by 
tobacco smoking,8 and stopping smoking at any age signifi-
cantly reduces lung cancer risk.9 10 LCS may provide a 
teachable moment for smoking cessation (SC);9 patients 
undertaking routine or acute visits to healthcare providers 
are more likely to be receptive to offers of help to quit.11
Several large studies have measured SC outcomes in the 
context of LCS, with results varying between higher quit 
rates,12 no difference13 or lower quit rates in screened 
versus unscreened participants.14 Despite the potential 
for important health gains, there is limited evidence 
on how best to integrate effective SC services in an LCS 
context, though lessons may be learnt from SC interven-
tions delivered in other settings.
Evidence suggests that provision of SC support as an 
opt- out default generates more quit attempts,15–17 and 
higher uptake within an LCS setting.18 A 2014 system-
atic review showed benefit of materials tailored to the 
characteristics of individual smokers,19 although the 
included studies were conducted predominantly in the 
general population, rather than screening participants. 
Further, a recent UK study has demonstrated the efficacy 
of including risk information personalised to pre- existing 
health conditions and consequences of continuing to 
smoke when inviting participants to SC services.20 LDCT 
screening commonly detects smoking- related comorbid-
ities, a consequence of participants’ long smoking histo-
ries.21 22 The screening process is a unique opportunity 
for a personalised SC intervention using these findings to 
improve quit rates.23
The SCALE collaboration in the USA consists of eight 
ongoing projects, and has recently been established to 
support projects testing a variety of SC interventions 
delivered in LCS settings involving LDCT. All share a 
common core of data collection measures to facilitate data 
sharing, which will build an evidence base for effective 
approaches.24 One approach not being tested within the 
SCALE collaboration is the use of incidental scan findings 
as part of the SC intervention. The Yorkshire Enhanced 
Stop Smoking (YESS) study intervention consists of a 
personalised paper- based booklet intervention incorpo-
rating images of the heart and lungs from the partici-
pant’s own LDCT scan. The booklet will be delivered by 
an SC practitioner (SCP) specially trained to deliver the 
intervention components, highlighting the short- term 
and long- term benefits of cessation while boosting self 
and response efficacy. To our knowledge, the YESS study 
is the first to test such an approach.
Study aims
The primary aims of the study are to:
1. Assess the uptake and effectiveness of a colocated opt- 
out SC intervention, delivered in line with National 
Health Service (NHS) standard best practice (SBP) 
guidance, as part of an LCS programme.
2. Assess the efficacy of a personalised, theory- grounded 
SC intervention, incorporating participant heart and 
lung scan images alongside an explanation of the clin-
ical importance of the findings and scripted communi-
cation to enhance personal salience, self- efficacy and 
response efficacy.
The secondary aims of the study are:
1. Conduct a process evaluation of both the colocated 
and personalised SC intervention to support interpre-
tation of study findings.
2. Conduct a health economic evaluation to assess the 
cost- effectiveness of the colocated service plus person-
alised feedback intervention over and above the colo-
cated service plus SBP.
METHODS
This protocol is reported in accordance with Standard 
Protocol Items: Recommendations for Interventional 
Trials guidance.25 Participant flow and study measures are 
summarised in figure 1.
Trial design
This is a pragmatic, parallel- group, open, randomised 
controlled trial comparing an enhanced, personalised 
SC support package, tailored to include results from 
LCS, delivered in addition to an SBP cessation package, 
versus SBP package alone. Further, we will also compare 
the effectiveness of the colocated service with local stop 
smoking services (SSS) in an observational design.
Participants and recruitment
Participants included in the YESS study will have been 
invited to attend a lung health check (LHC) (including 
LDCT screening for lung cancer) as part of the York-
shire Lung Screening Trial (YLST) (funded by Yorkshire 
Cancer Research, award reference L403, 2016 round 
REC reference 18/NW/0012).26 In brief, participants are 
aged 55–80, registered with a general practitioner (GP) 
in the Leeds Clinical Commissioning Group area and 
registered as a current or ex- smoker in primary care data-
bases. Participants will be considered eligible for LDCT 
screening if they meet the criteria of either USPSTF,27 
PLCOM2012
28 or LLP (v2)29 models.
Inclusion criteria
All individuals who attended an LHC and consent to 
participate in the YLST, have smoked within the last 
month or have an exhaled carbon monoxide (CO) 
reading ≥6 ppm and have agreed to see an SCP on the 
mobile unit.
Exclusion criteria
Any individual who does not have an LDCT scan, or is 
unable to provide informed consent.
Participant withdrawal
Participants may be withdrawn from the trial either at 
their own request or at the discretion of the Investigator. 
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Participants will be made aware that this will not affect 
their future care.
Randomisation
After the screening visit, but before the 4- week follow- up, 
all smokers who agreed to see the SCP will be randomised 
to either continued SBP or intervention using concealed 
allocation. The randomisation sequence (1:1 in permuted 
blocks of random size up to size 6) will be generated using 
a computer random- number generator and participants 
allocated sequentially, overseen by the University of 
Nottingham clinical trials unit.
Blinding
The sequence of treatment allocations will be concealed 
until interventions have all been assigned and recruit-
ment and data collection are complete. Once primary 
and secondary data from both treatment groups have 
been analysed by the trial statistician, the groups will 
be un- blinded to the Trial Management Group (TMG). 
Consent is taken at the 4- week visit by the SCP. In order to 
ensure concealment at the time of recruitment/consent, 
the personalised risk information booklet (further detail 
provided later) or a blank booklet are enclosed in a 
sealed envelope which is opened by the SCP following 
consent/data collection. This arrangement commenced 
five rounds into recruitment following review of processes 
at a Trial Steering Committee. For five rounds at the start 
of the trial, SCPs were aware of trial allocation at the time 
of consent/data collection. The impact of this will be 
assessed in a sensitivity analysis.
Sample size
Recruitment will be limited to the number of eligible 
smokers attending for an LHC over the 2- year YLST 
recruitment period. Based on early recruitment figures, 
we anticipate 1040 smokers enrolling in YESS.
Those in the SBP group will be provided with a service 
similar to that provided by national NHS SSS. A 2010 
systematic review of relapse rates among smokers quit-
ting with national NHS SSS found that 53% had quit at 1 
month, and 15% at 1 year.30 Fitting an exponential decay 
function to these figures we estimate a monthly relapse 
rate, after 1 month, of 11.5%. Applying these figures to 
our study design we would expect a quit rate of 41% at 3 
months in those receiving SBP. If the cessation rate is 41% 
in the usual care group, a study of 1040 individuals will 
provide 90% power to detect an increase to 51% (ie, an 
increase of 10%), and 80% power to detect an increase to 
49.6% (ie, an increase of 8.6%).
Study duration
Participants will be recruited to YESS between January 
2019 and December 2020 with follow- up data collection 
ending December 2021. Stop smoking support will be 
provided for as long as the participant requires, up to 12 
Figure 1 Flow diagram illustrating the path of participants through the study, interventions and evaluations. LDCT, low- dose 
CT; SCP, smoking cessation practitioner; YLST, Yorkshire Lung Screening Trial; SSS, stop smoking service
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weeks. Follow- up contact will be requested at 4 weeks, 3 
months and 12 months, with a 2- week window to accom-
modate participant availability. The latter will also apply 
to interviews conducted for the process evaluation.
SC provision
All eligible smokers
Unless explicitly declined, all eligible YLST participants 
will attend a consultation with a specialist SCP, trained to 
National Centre for Smoking Cessation and Training stan-
dards,31 colocated within the screening van. Support will 
be provided in line with National Institute for Health and 
Care Excellence (NICE) PH48 guidance32 comprising 
one session of behavioural support at the time of the 
LHC and provision of pharmacotherapy (either as nico-
tine replacement therapy through delegated prescribing 
at the visit and/or a commercially available e- cigarette, or 
arrange a GP prescription for varenicline or bupropion). 
Follow- up contact either face- to- face or by telephone, 
typically weekly but more or less frequently according to 
participant preference for up to 4 weeks from the date of 
the LHC.
Where study SCP follow- up is not possible, or if the indi-
vidual smoker prefers, contact details will be passed to the 
local NHSSSS for referral into community services imme-
diately following the screening visit.
All eligible participants will be asked for consent to 
be contacted by telephone at 4 weeks, 3 months and 12 
months after the screening visit solely to ascertain smoking 
status, with optional CO validation if quit. Approximately 
4 weeks after the screening visit (and hence after scan 
results have been issued by YLST), the SCP will arrange 
a face- to- face visit with the smoker either at home or 
community location (according to the participant’s pref-
erence) to ascertain current smoking status (with CO vali-
dation in those reporting abstinence). Informed written 
consent for participation in the trial will be confirmed at 
this visit, and individuals treated according to their allo-
cated group as follows:
SBP group
Pharmacotherapy/e- cigarettes and behavioural support 
will continue to be offered and arranged, as outlined 
above.
Intervention
Personalised booklet with LDCT scan images
In addition to SBP and YLST standard feedback, partic-
ipants are provided with information about their scan 
findings in a personalised booklet. Where the reporting 
radiologist has identified emphysema or coronary artery 
calcification (CAC), a trained research radiographer 
will select appropriate images for use in the booklet. All 
images are accompanied by brief text to provide context 
and explanation.
Where the participant’s scan shows emphysema, an 
axial image displayed using lung windows that best 
demonstrates this will be extracted, and a red outline 
drawn around the emphysematous area to highlight this 
finding. Where possible, an image from another part of 
the participant’s scan showing normal lung parenchyma 
will be shown alongside the emphysematous image to 
highlight that there are areas of healthy lung than can be 
protected by SC. Where emphysema is present throughout 
both lungs, an image will be selected showing an area 
of relative sparing. Where emphysema is not present 
at all, an image of the participant’s normal lung will be 
shown alongside a library scan image of severe emphy-
sema. An artists’ impression of a lung, showing healthy 
and damaged emphysematous areas will be included to 
aid participant comprehension (see figure 2A–C, for 
examples).
Where CAC is present, the axial image displayed using 
mediastinal windows that best demonstrates this will be 
extracted and shown alongside an artist’s impression 
of the heart, with the corresponding area of calcifica-
tion annotated with yellow shading. Where CAC is not 
present, the participants’ own normal scan image will 
be shown alongside an artist’s impression of the heart 
demonstrating what might happen were the participant 
to continue smoking. In all cases, an additional artist’s 
impression of health and narrowed coronary arteries are 
shown (see figure 2D,E, for examples). Five per cent of all 
booklets produced will be audited by a respiratory physi-
cian or radiologist to ensure that appropriate images, 
annotations and text are used in the resource.
The booklet will also contain generic short- term and 
longer- term benefits of quitting derived from the Smoke-
free NHS website33 and contact details for the YESS study 
project manager, the local NHSSSS, the YLST clinical 
team and the assigned SCP.
Scripted communication to explain clinical importance and target 
behavioural components
The SCP will explain the biological nature of emphysema 
and CAC and will provide feedback and further SC advice 
tailored to the result. The SCP will highlight specific bene-
fits to risks of lung cancer, Chronic Obstructive Pulmo-
nary Disease (COPD) or cardiovascular disease arising 
from quitting including the reduced progression of 
existing emphysema or smoking- damage. SCP’s commu-
nication about the personalised risk booklet is supported 
by scripts which exemplify how each section should be 
communicated in each of the different result scenarios. 
The scripts model communication techniques and 
language designed to target the behavioural intervention 
components; specifically, to increase personal salience, 
self- efficacy and response- efficacy, while mitigating the 
potential for anxiety and over- reassurance. They use lay 
language to illustrate the steps of disease progression and 
emphasise the short- term and immediate benefits of quit-
ting for participants’ health. This scripted approach also 
aims to help standardise intervention delivery. Where 
required, participants are offered the opportunity for a 
telephone consultation with a respiratory physician to 
discuss scan findings.
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Data collection
Data collection measures are summarised in table 1.
Outcome measures
Primary outcome
Seven day point prevalent CO validated SC 3 months 
after the LHC in all participants enrolled in the YESS 
study.
Secondary outcomes
 ► Self- reported and CO validated continuous cessation 
at 4 weeks in all eligible smokers agreeing to receive 
SC from the SCP as part of the LHC.
 ► Self- reported continuous and seven day point preva-
lent SC at 3 months.
 ► Self- reported and CO validated continuous cessation 
at 12 months.
 ► Attempts to quit smoking.
 ► Changes in psychological variables, including 
perceived risk of lung cancer, motivation to quit 
smoking tobacco, confidence and efficacy beliefs (self 
and response) at all follow- up points.
Process evaluation
Approximately 30 semistructured interviews (10 at each 
follow- up time point) with be conducted with interven-
tion participants, or until data saturation, to evaluate 
intervention usage, comprehension and acceptability. 
Fifteen SBP group participants (five at each time point) 
will be interviewed to assess potential study contamina-
tion. Interviews will also explore whether participants 
received any additional risk information or SC advice 
from healthcare professionals as part of their LHC or 
during any nodule follow- up. Participants will be purpo-
sively sampled by age (≤65 years, >65 years), gender, quit 
motivation, quit status (at 3 and 12 months) and scan 
findings (ie, CAC present or absent; emphysema absent, 
present with areas of normal lung elsewhere or diffusely 
present throughout both lungs) across all interview 
time- points where possible. Interviews will be conducted 
across the 2- year trial recruitment timeframe, face- to- face 
or by telephone according to preference. Participants 
will be offered a shopping voucher as an inconvenience 
allowance.
All SCPs in post will be invited to take part in an inter-
view across the three follow- up time points to explore 
Figure 2 Example of a booklet page for (A) participant with no visible emphysema; (B) participant with ‘moderate’ emphysema; 
(C) participant with ‘severe’ emphysema; (D) participant with no visible coronary artery calcification (CAC); (E) participant with 
CAC.
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which aspects of the intervention were perceived to influ-
ence change, gain insight into contextual barriers and 
facilitators of embedding the personalised intervention 
into practice and intervention fidelity.
Audio- recordings of SCP sessions will take place (10% 
across both arms) across the 2- year recruitment period 
to assess intervention fidelity. Sessions to be recorded 
will be purposefully sampled by SCP, quit motivation 
(where possible), age (≤65 years, >65 years) and gender 
(men/women). Fidelity will be ascertained by a trained 
researcher listening to the audio- recordings and coding 
the appropriate delivery of materials against SBP and stan-
dard care plus personalised risk information. To comple-
ment session audio- recordings and SCP interviews, SCPs 
will be asked to self- report fidelity (intervention elements 
were delivered as intended) and dose (how much of the 
intervention was delivered).
All interviews will be audio- recorded using an encrypted 
recorder with permission, transcribed verbatim and 
anonymised. The audio recording will be labelled using 
the participant’s unique identification number assigned 
during YLST and transferred to an external transcribing 
service. Audio- files will be destroyed after analysis is 
complete.
Economic evaluation
An economic evaluation will assess the cost- effectiveness 
of the personalised feedback intervention over and above 
standard care. An NHS perspective will be adopted in 
line with NICE guidance. We will record and calculate 
the costs of providing the colocated service, the SBP 
and the intervention prospectively throughout the trial, 
in terms of staff time, overheads, pharmacotherapy and 
other consumables. We will also record patients’ utilisa-
tion of primary and secondary healthcare services outside 
of the trial using a short self- report questionnaire. The 
primary health outcome in the economic evaluation is 
assessed in terms of quality- adjusted life years (QALYs). 
The EuroQoL EQ- 5D- 3L questionnaire will be used 
to measure health- related quality of life and calculated 
QALYs using the area under the curve approach.34 Ques-
tionnaires will be administered at baseline, 3- month and 
12- month follow- up.
Non-participants
Eligible participants who attend for an LHC but opt- out 
of receiving SC support, or receive SC support but do not 
consent to participate in the YESS study will be asked to 
complete a brief questionnaire detailing their reasons for 
declining. Further, individuals who receive SC support 
but do not consent to participate in the YESS study will 
be asked to provide consent to be contacted at 3 and 12 
months to ascertain smoking status only.
Additionally, we will purposively sample approximately 
30 non- participants by quit motivation (where possible), 
age (≤65 years, >65 years) and gender for interview to 
understand their reasons for non- participation. Inter-
views will be carried out face- to- face or by telephone, 
according to preference, and participants will be offered 
a shopping voucher. Where possible interviews will be 
conducted within a 2- week window after declining. We 
will conduct interviews across the 2- year trial recruitment 
timeframe. Consent for interviews with those who decline 
will be obtained via telephone according to a stan-
dardised consent script. Information sheets and a copy 
of the consent script will be sent to participants prior to 
interview.
Comparative measurement in those smokers attending community 
stop smoking services
Anonymised data will be provided for those aged 55–80 
years for dates corresponding to the study period from 
the local NHSSSS to compare quit outcomes in those 
receiving SC support through YESS with those accessing 
community services.
Assessment of adverse events
Adverse events arising during the trial will be managed in 
accordance with standard clinical practice, recorded by 
the trial manager. Electronic cigarette use by participants 
will be recorded and participants will be able to report 
their experience at the 4- week, 3- month and 12- month 
follow- up assessments.
Data management and monitoring
Monitoring of trial data shall include: confirmation of 
informed consent; source data verification; data storage 
Table 1 Data collection measures in study participants
Baseline
4 
weeks
3 
months
12 
months
Smoking behaviour 
(including CO 
validation if 
abstinence is 
reported)
X X X X
Motivation to quit 
smoking
X X X X
Quit confidence X X X X
Self- efficacy of 
quitting smoking
X X X X
Use of smoking 
cessation support
X     X
Wider healthcare 
resource use
X   X X
Response efficacy 
of quitting smoking
  X X X
Perceived risk of 
cancer developing 
cancer
  X X X
Cancer worry score   X X X
Quality of life (EQ- 
5D- 5L)
X   X X
CO, carbon monoxide.
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and data transfer procedures; local quality control checks 
and procedures, back- up and disaster recovery of any local 
databases and validation of data manipulation. Entries 
on case report forms (CRF) will be verified by inspection 
against the source data. A sample of CRFs (10% or as per 
the study risk assessment) will be checked on a regular 
basis for verification of all entries made. In addition, the 
subsequent capture of the data on the trial database will 
be checked. Interview transcripts will be checked against 
audio- recordings for accuracy. Where corrections are 
required these will carry a full audit trail and justification. 
Trial data will be stored and maintained on Nottingham 
or Cardiff University respective servers. When and if data 
are transferred it will be conducted in a controlled/veri-
fied manner in accordance with a data management plan 
and the University of Nottingham’s ‘Handling Personal 
Data’ policy.
Statistical analyses
We will compare baseline characteristics between 
randomised treatment groups descriptively. We will esti-
mate the effect of the intervention by comparing our 
primary and secondary outcomes between intervention 
and SBP groups using logistic regression, presenting 
results in terms of the proportion achieving abstinence 
in the two groups, the risk difference and the OR, with 
95% CIs.
Primary analysis will be on an intention to treat basis, 
assuming that missing data implies smoking, but we will 
conduct sensitivity analysis to examine the impact on 
our findings of alternative assumptions, including the 
Hedeker approach which assumes alternative relation-
ships between having missing data and smoking, and 
using multiple imputation to test the alternative assump-
tion that the data are missing at random (ie, missing data 
can be modelled using measured variables).
We do not plan a priori to adjust for any baseline 
covariate, presuming that randomisation will achieve 
balance between groups. We will look for effect modi-
fication of effect of intervention according to presence 
of absence of abnormal scan findings of emphysema or 
CAC, using the likelihood ratio test for interaction. In 
sensitivity analysis, we will analyse excluding those who 
were consented to the intervention group prior to change 
in timing of consent (n=94).
Comparative measurement in those smokers attending community 
stop smoking services
We will compare cessation rates at 4 weeks between the 
intervention and SBP groups with those smokers aged 
55–80 attending the local stop smoking service over 
the same time period to delineate the effect of both SC 
interventions within YESS, using logistic regression and 
adjusting for observed baseline differences in predictors 
of cessation including age, gender, heaviness of smoking 
and level of education.
A detailed statistical analysis plan will be prepared prior 
to completion of trial recruitment, and agreed with the 
trial steering committee.
Economic analysis
An incremental cost- effectiveness analysis will be conducted 
alongside the trial to assess the cost- effectiveness of the 
personalised feedback intervention over and above stan-
dard on an intention- to- treat basis. An NHS perspective 
will be adopted in line with NICE guidance.35 Costs will be 
calculated using national average unit costs multiplying 
the reported level of healthcare resource use. A total 
healthcare cost profile for all patients in each trial arm is 
then constructed by adding the costs of the intervention 
and standard care to the wider NHS costs. The economic 
evaluation will use validated quit rates at 12 months to 
estimate the incremental cost per QALY afforded by the 
intervention over and above SBP. The results presented 
will indicate the NHS cost of funding the intervention in 
order to gain one additional QALY at 12 months.
To handle the problem of missing trial data, we will 
conduct a sensitivity analysis employing Rubin’s multiple 
imputation method.36 Thirty multiple imputation (MI) 
data sets will be generated using the Multiple imputation 
(MI) command in STATA v.16. The outcomes of the sensi-
tivity analysis will be used to test the impact of missing 
data on the results. To account for uncertainty due to 
sampling variation in cost- effectiveness, we will under-
take a non- parametric bootstrapping on the incremental 
cost and effectiveness with 50 000 replications.37 Cost- 
effectiveness acceptability curves will be plotted based 
on the bootstrap iterations to show the probability of the 
intervention being more cost- effective than the standard 
care over a range of a decision- maker’s willingness- to- pay 
thresholds.38
Process evaluation analysis
The process evaluation will be reported in line with 
Enhancing the QUAlity and Transparency Of Health 
Research guidelines.39 Anonymised interview transcripts 
will be analysed using a Framework approach40 with the 
aid of NVivo software41 or Microsoft Excel V.16 where 
appropriate for indexing. Themes will be derived initially 
from the process evaluation aims and topic guides, with 
additional themes emerging from the data. The analytic 
framework will be refined by double- coding 20% of the 
interviews. Analysis of intervention and SBP, trial non- 
participant and SCP interviews will be conducted sepa-
rately, with comparisons made between the themes 
identified within the respective analyses. If the Motivation 
to Stop Smoking scale42 is used during interviews with 
non- participants, the response will be recorded where 
appropriate and a descriptive analysis will be conducted 
for interpretation alongside the qualitative interview data.
Audio- recordings will be analysed for context, fidelity 
and exposure. Fidelity will be assessed through the coding 
of intervention components delivered against those pre- 
set for standard care or standard care plus personalised 
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risk information. Coding will take place on a stan-
dardised proforma (developed prior to study commence-
ment), and a fidelity definition and acceptable range 
will be agreed on in advance. Twenty per cent of audio- 
recordings will be double- coded independently (10% of 
recordings across both arms). Descriptive statistics will be 
used to report intervention fidelity.
Closed- ended questions from SCP self- report data will 
be analysed using descriptive statistics to assess interven-
tion fidelity and dose, using Microsoft Excel V.16 or SPSS 
V.26.43 Open- ended questions will be thematically anal-
ysed using NVivo.41 Free text data from non- participant 
questionnaires will be thematically analysed44 using 
NVivo, with 20% double- coded.
Trial data used to support the process evaluation will 
be analysed in line with the YESS trial statistical analysis 
plan. Descriptive analysis will be used to ascertain trial 
recruitment and retention and add to qualitative data on 
context, reach and exposure.
Ethical approval, research governance, trial sponsorship and 
registration
This study was approved by the East Midlands- Derby 
Research Ethics Committee (REC reference: 18/
EM/0199) and HRA/HRCW on 31 August 2018. Subse-
quent amendments are detailed in table 2.
This study was adopted onto the National Institute for 
Health Research trial portfolio on 18 September 2018 
and is sponsored by the University of Nottingham. Any 
planned modifications to the protocol will be approved 
by the REC before they are adopted by the study. An 
audit trail of ethical amendments, documentation and 
data collection will be kept to allow monitoring by the 
research team and external regulatory bodies.
The trial was registered with the International Standard 
Randomised Controlled Trial Number (ISRCTN) on 25 
September 2018 and the National Institutes of Health  
ClinicalTrials. gov database on 21 November 2018.
Study management
The TMG is comprised the principal investigator, clinical 
and academic coapplicants and collaborators who will 
jointly monitor trial conduct and progress. All aspects of 
the study, and study personnel, will adhere to the full clin-
ical trial protocol (version 2.2 or subsequent approved 
version), Good Clinical Practice guidelines and General 
Data Protection Regulations.
A Trial Steering Group comprising independent 
experts in the fields of cancer screening, respiratory 
medicine, SC, radiology and statistics, and a patient/
public representative will meet with key members of the 
TMG at approximately 6- month intervals throughout the 
trial recruitment phase to oversee this study and agree 
any amendments to the protocol.
DISCUSSION
The YESS study will address a number of questions 
directly relevant to the implementation of a smoking 
cessation intervention within LCS services. It will provide 
evidence as to the uptake, effectiveness and acceptability 
of an SC service colocated within a screening programme, 
and the efficacy and acceptability of providing a person-
alised stop smoking intervention which incorporates 
incidental findings detected as part of the LDCT scan 
supported by communication that supports self- efficacy 
and response- efficacy. Given the current interest in LCS 
programmes and the potential for adoption and imple-
mentation in many countries, the YESS study is timely 
Table 2 Summary of ethical amendments
Protocol Date Summary of changes
V2 16 October 
2018
Re- formatting of consent forms to fit within one A4 page (minor).
V2.1 29 March 
2019
Amendment to letters informing/seeking guidance from participants’ general practitioner regarding 
potential contraindications for nicotine replacement therapy and requesting varenicline prescriptions.
Minor amendments to interview topic guides.
Change to incentive amounts.
Audio recording of a sample of initial consultation interactions (substantial).
V2.2 03 June 
2019
Change timing of consent to YESS trial—not implemented.
V2.1 26 July 
2019
Submission of YESS subsection 1 and 2 participant information sheet (V.1 17 05 2019) as they were 
omitted from the original application (substantial).
V2.2 11 
November 
2019
Reduction in recruitment target from 2019 to 1040 to reflect the number of smokers enrolling in YLST 
(substantial).
YESS, Yorkshire Enhanced Stop Smoking; YLST, Yorkshire Lung Screening Trial.
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and will potentially inform related policy decisions and 
recommendations.
Study findings will be written in accordance with 
Consolidated Standards of Reporting Trials guidelines,45 
submitted for publication to relevant peer- reviewed jour-
nals, presented at conferences and published on the rele-
vant section of the YLST website. A summary of results 
will be provided to any participant on request.
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